The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.

The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...

Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...

“They [create] significant clinical and public health challenges as well as the need for further research.” One author disclosed ties to Amgen and UBC.

AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested ...

One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...

The donation to Rush’s orthopedic department, the largest ever, creates four new endowed positions and programs.

Shares of Amgen Inc. AMGN inched 0.08% higher to $278.32 Tuesday, on what proved to be an all-around mixed trading session ...

Patients with recurrent platinum-sensitive ovarian cancer did just as well with cytoreductive surgery alone as they did with ...

Following a pair of similar deals in January and June, Coherus BioSciences has netted itself a hefty chunk of change for the ...

German biotech asks federal judge to reject Amgen’s efforts to narrow scope of a key patent in ongoing dispute | Patent ...